<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="with high-level resistance to all NRTIs, first generation NNRTIs, all" exact="ritonavir" post="boosted protease inhibitors (PI/r), and all INSTI, while viral"/>
 <result pre="a false positive rate (FPR) of 60.9% suggesting effectiveness of" exact="maraviroc" post="(MRV). The third GRT showed high-level resistance to NRTI,"/>
 <result pre="for 14 years (since 2006). His initial ART regimen was" exact="stavudine" post="(d4T)â€‰+â€‰lamivudine (3TC)â€‰+â€‰nevirapine (NVP) from August 2006 to August 2007."/>
 <result pre="August 2006 to August 2007. NVP was subsequently replaced by" exact="efavirenz" post="(EFV) from August 2007 to August 2009. From August"/>
 <result pre="Following clinical assessment, he received a regimen consisting of super-boosted" exact="ritonavir" post="with darunavir (DRV/r)â€‰+â€‰raltegravir (RAL)â€‰+â€‰tenofovir (TDF) +3TC (unclear start date)"/>
 <result pre="clinical assessment, he was re-initiated with a regimen consisting of" exact="ritonavir" post="boosted darunavir (DRV/r)â€‰+â€‰raltegravir (RAL)â€‰+â€‰tenofovir (TDF) +3TC (unclear start date)"/>
 <result pre="mutational profile suggested DRV/r(600â€‰mg Ã—â€‰2/day)â€‰+â€‰DTG(50â€‰mg Ã—â€‰2/day), possibly associated with ritonavir-boosted" exact="atazanavir" post="(ATV/r) for its potential capacity to enhance DTG concentrations"/>
 <result pre="E157Q, to integrase strand transfer inhibitors (INSTI) including raltegravir, dolutegravir," exact="bictegravir" post="and elvitegravir. Viral tropism revealed a CCR5-tropic virus, defined"/>
 <result pre="a false positive rate (FPR) of 60.9%, suggesting eligibility for" exact="maraviroc" post="(MRV). The third GRT (August 08, 2019), encompassing PR,"/>
 <result pre="drugs in resource-limited settings with similar ART landscapes. Abbreviations 3TC" exact="Emtricitabine" post="ABC Abacavir ADR Acquired drug resistance AIDS Acquired Immunodeficiency"/>
 <result pre="resource-limited settings with similar ART landscapes. Abbreviations 3TC Emtricitabine ABC" exact="Abacavir" post="ADR Acquired drug resistance AIDS Acquired Immunodeficiency Syndrome ART"/>
 <result pre="drug resistance AIDS Acquired Immunodeficiency Syndrome ART Antiretroviral therapy ATV/r" exact="Ritonavir" post="boosted Atazanavir CCR5 C-C chemokine receptor type 5 CD4"/>
 <result pre="AIDS Acquired Immunodeficiency Syndrome ART Antiretroviral therapy ATV/r Ritonavir boosted" exact="Atazanavir" post="CCR5 C-C chemokine receptor type 5 CD4 Cluster of"/>
 <result pre="of differentiation four CRF18_cpx Circulating recombinant form complex 18 D4T" exact="Stavudine" post="DRV/r Ritonavir boosted Darunavir DTG Dolutegravir EFV Efavirenz FPR"/>
 <result pre="four CRF18_cpx Circulating recombinant form complex 18 D4T Stavudine DRV/r" exact="Ritonavir" post="boosted Darunavir DTG Dolutegravir EFV Efavirenz FPR False positive"/>
 <result pre="18 D4T Stavudine DRV/r Ritonavir boosted Darunavir DTG Dolutegravir EFV" exact="Efavirenz" post="FPR False positive rate GP 120 Envelope glycoprotein 120"/>
 <result pre="drug resistance IN Integrase INSTI Integrase strand transfer inhibitor LPV/r" exact="Ritonavir" post="boosted Lopinavir MRV Maraviroc NNRTI Non-nucleoside reverse-transcriptase inhibitor NRTI"/>
 <result pre="Maraviroc NNRTI Non-nucleoside reverse-transcriptase inhibitor NRTI Nucleoside reverse-transcriptase inhibitor NVP" exact="Nevirapine" post="PDR Pretreatment drug resistance PI/r ritonavir boosted protease inhibitor"/>
 <result pre="Nucleoside reverse-transcriptase inhibitor NVP Nevirapine PDR Pretreatment drug resistance PI/r" exact="ritonavir" post="boosted protease inhibitor Pol Polymerase PR Protease RAL Raltegravir"/>
</results>
